

ACG 2012 All Scores Report by Category and Score - Blinded

I, IBD 10/2 Scale / Best to 10 Worst

Control ID	Cat	Avg	Rank Cat	Rank All	Poster Only	ACG Grant	Rev1	Rev2	Rev3	Rev4	Country	TITLE
1382513	I1	1.5	1	7			2 Rev1	2 Rev2	1 Rev3	1 Rev4	Canada	Vedolizumab Maintenance Therapy for Ulcerative Colitis: Results of GEMINI I, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase 3 Trial
1416332	I1	1.5	2	8			2 Rev1	2 Rev2	1 Rev3	1 Rev4	United States	Vedolizumab Maintenance Therapy for Crohn's Disease: Results of GEMINI II, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase 3 Trial
1402529	I1	2.25	5	39			2 Rev1	4 Rev2	2 Rev3	1 Rev4	United States	Venous thromboembolism risk and anti-tumor-necrosis alpha agents in inflammatory bowel disease and other chronic inflammatory diseases
1430759	I1	2.5	8	59			3 Rev1	3 Rev2	2 Rev3	2 Rev4	United States	Disproportionate Lawyer Reporting of Inflammatory Bowel Disease Cases with Isotretinoin: A Review of the Food and Drug Administration (FDA) Adverse Event Reporting System (AERS)
1414083	I1	2.75	11	95			2 Rev1	5 Rev2	2 Rev3	2 Rev4	United States	Predictors of Colorectal Neoplasia Outcomes in Indefinite and Low Grade Dysplasia in Patients with Primary Sclerosing Cholangitis and Ulcerative Colitis
1425110	I1	2.75	12	96			2 Rev1	4 Rev2	1 Rev3	4 Rev4	United States	Vedolizumab Induction Therapy for Crohn's Disease: Results of Gemini II, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase 3 Trial
1428872	I1	2.75	13	97			4 Rev1	3 Rev2	1 Rev3	3 Rev4	United States	Human Placenta-Derived Cells (PDA001) for the Treatment of Moderate-to Severe Crohn's Disease: Results of a Phase 1b/2a Study
1425254	I1	3	18	165			3 Rev1	4 Rev2	3 Rev3	2 Rev4	United States	Comparison of Health Care Utilization and Costs Among Patients With Fistulizing Crohn's Disease Treated With Biologics With or Without Prior Seton Procedure
1434977	I1	3	19	166			3 Rev1	5 Rev2	3 Rev3	1 Rev4	United States	Increased Risk of Herpes Zoster among Patients with Inflammatory Bowel Disease
1435049	I1	3	20	167			2 Rev1	6 Rev2	2 Rev3	2 Rev4	United States	Lower infliximab use in African American compared to Caucasian IBD patients: analysis of a large U.S. comparative hospital database
1426885	I1	3.25	23	251			4 Rev1	5 Rev2	2 Rev3	2 Rev4	United States	Cancer Risk in a Population-Based Cohort of Inflammatory Bowel Disease
1428044	I1	3.25	24	252			5 Rev1	3 Rev2	2 Rev3	3 Rev4	United States	Long term effects of 5-aminosalicylic acid use on renal function in the elderly with inflammatory bowel disease.
1428418	I1	3.25	25	253	X		4 Rev1	4 Rev2	3 Rev3	2 Rev4	United States	Development of a Novel Assay to Monitor Neutralizing Anti-drug Antibody Formation in IBD Patients
1431716	I1	3.25	26	254			5 Rev1	2 Rev2	3 Rev3	3 Rev4	United States	Indigo carmine staining increases the yield for dysplasia in ulcerative colitis among inexperienced endoscopists: Implementation of a chromoendoscopy program
1432596	I1	3.25	27	255			3 Rev1	5 Rev2	3 Rev3	2 Rev4	United States	The Association Between Microscopic Colitis and Cellac Disease: A Population-based Study
1382471	I1	3.5	31	360			3 Rev1	5 Rev2	3 Rev3	3 Rev4	United States	Direct and Indirect Utilization and Costs Associated With Ulcerative Colitis
1384377	I1	3.5	32	361			3 Rev1	4 Rev2	3 Rev3	4 Rev4	Netherlands	Mucosal Healing in Ulcerative Colitis Patients with Week 8 Response to Adalimumab: Subanalysis of ULTRA 2

ACG 2012 All Scores Report by Category and Score - Blinded

Control ID	Cat	Avg	Rank Cat	Rank All	Poster Only	ACG Grant	Revisions				Country	TITLE
							Rev1	Rev2	Rev3	Rev4		
1414197	11	3.5	33	362			3	5	3	3	United States	Clinical Features and Treatment Responses in Pediatric Lymphocytic and Colлагенous Colitis
							Rev1	Rev2	Rev3	Rev4		
1415673	11	3.5	34	363			3	5	3	3	United States	Rate of and Response to Dose Escalation in Patients Treated With Adalimumab for Moderately to Severely Active Ulcerative Colitis: Subanalysis of ULTRA 2
							Rev1	Rev2	Rev3	Rev4		
1423180	11	3.5	35	364			4	5	3	2	United States	Use of Anti-TNF Agents in Crohn's Disease Is Associated With Larger Reductions in Diagnostic Imaging and Radiation Doses Compared With Systemic Steroids in the Year Following Initiation of Therapy
							Rev1	Rev2	Rev3	Rev4		
1426049	11	3.5	36	365	X		4	3	4	3	Canada	Pharmacokinetic Profiles for Oral and Subcutaneous Methotrexate in Patients with Crohn's Disease
							Rev1	Rev2	Rev3	Rev4		
1426712	11	3.5	37	366			5	4	3	2	United States	Azathioprine versus methotrexate as adjuvant therapy with infliximab in biologic naive patients: equivalent responses over three year follow up
							Rev1	Rev2	Rev3	Rev4		
1432174	11	3.5	38	367			4	5	3	2	United States	Treatment Benefit-Risk Preferences of Patients with Early Crohn's Disease
							Rev1	Rev2	Rev3	Rev4		
1418036	11	3.67	45	387			4	CI	3	4	United States	Outcomes of Pregnancy in Subjects Exposed to Certolizumab Pegol
							Rev1	Rev2	Rev3	Rev4		
1385836	11	3.75	48	488			3	4	3	5	Belgium	Reduced Steroid Usage in Ulcerative Colitis Patients With Week 8 Response to Adalimumab: Subanalysis of ULTRA 2
							Rev1	Rev2	Rev3	Rev4		
1410866	11	3.75	49	489			4	5	3	3	United States	Identification of Clinical and Genetic Risk Factors in the Development of Chronic Pouchitis
							Rev1	Rev2	Rev3	Rev4		
1419047	11	3.75	50	490	X		5	3	4	3	United States	Comparison of techniques for monitoring infliximab and antibodies to infliximab in Crohn's disease patients with infliximab treatment failure
							Rev1	Rev2	Rev3	Rev4		
1429146	11	3.75	51	491	X		3	5	2	5	United States	Preventive Care Quality Outcomes in an Inflammatory Bowel Disease Population
							Rev1	Rev2	Rev3	Rev4		
1433004	11	3.75	52	492			5	5	3	2	Canada	Adalimumab Induction Dose Reduces the Risk of Hospitalizations and Colectomies in Patients With Ulcerative Colitis During the First 8 Weeks of Therapy
							Rev1	Rev2	Rev3	Rev4		
1434646	11	3.75	53	493			3	5	3	4	United States	Predictors of Disability in Patients With Crohn's Disease
							Rev1	Rev2	Rev3	Rev4		
1403981	11	4	66	650	X		5	4	4	3	United States	Utility of parasite investigation in IBD: Just Because We Can Doesn't Mean We Should.
							Rev1	Rev2	Rev3	Rev4		
1404413	11	4	67	651			4	4	3	5	United States	The Association of Inflammatory Bowel Disease and Abnormal Pap Smears in Black Women.
							Rev1	Rev2	Rev3	Rev4		
1424934	11	4	68	652	X		6	3	4	3	United States	Recognition of the p53 Null Staining Pattern Increases the Detection of p53 Alterations in Inflammatory Bowel Disease-Associated Carcinomas
							Rev1	Rev2	Rev3	Rev4		
1426713	11	4	69	653			5	5	3	3	United States	Increasing Percentage of TNF Inhibitor Induced Psoriasis: A Review of the Food and Drug Administration Adverse Event Reporting System (AERS)
							Rev1	Rev2	Rev3	Rev4		

1=Excellent - 9=Poor (C=Conflict of Interest)

ACG 2012 All Scores Report by Category and Score - Blinded

Control ID	Cat	Avg	Rank	All	Rank	Poster Only	ACG Grant	TITLE					Country
								Rev1	Rev2	Rev3	Rev4		
1427885	11	4	70	654		X		5	4	3	4	United States	Significance of Granulomatous Inflammation Found on Endoscopic Biopsies or Surgical Resections on the Severity and Prognosis of Crohn's Disease
1430534	11	4	71	655				4	5	2	5	United States	Novel STAT3 selective inhibitor Natura-α shows great promises in treating moderate-to-severe ulcerative colitis in a randomized, double-blind, placebo-controlled Phase II clinical trial
1430882	11	4	72	656				6	4	4	2	United States	Analysis of Prevalence and Risk Factors for Active Disease of Crohn's Disease Patients for Acute Exacerbation Symptoms
1432088	11	4	73	657				4	4	4	4	United States	Cost-Effectiveness of Adalimumab in Moderately to Severely Active Ulcerative Colitis
1432147	11	4	74	658				3	5	6	2	United States	Time-in-Remission Analysis of Adalimumab vs. Placebo for the Treatment of Ulcerative Colitis
1418098	11	4.25	83	795				4	6	3	4	United States	Smoking and Infliximab response in Crohn's disease: a Meta-analysis.
1426635	11	4.25	84	796				6	4	3	4	United States	Differential response to microbial antigens by age of diagnosis in patients with Crohn's disease
1426750	11	4.25	85	797				4	4	4	5	United States	Comparison of standard dose azathioprine versus low dose azathioprine when used as adjuvant therapy with infliximab in patients with inflammatory bowel disease
1428994	11	4.25	86	798				7	5	3	2	United States	Systematic Review on the Efficacy of Anti-inflammatory Agents, Immuno-modulators and Biological Agents as Post-Operative Prophylaxis to Prevent Recurrence of Crohn's Disease
1432196	11	4.25	87	799				4	5	4	4	Canada	Adalimumab Therapy Reduces Hospitalization and Colectomy Rates in Patients With Ulcerative Colitis Among Initial Responders
1432986	11	4.25	88	800				4	5	3	5	United States	Vaccinations in Patients with Inflammatory Bowel Disease and Rheumatoid Arthritis on Immunosuppressants: Primary Care Physician Awareness and Current Practices at a Tertiary Care Center
1434644	11	4.25	89	801				4	5	3	5	United States	Preventing Patients with Crohn's Disease from Discontinuing Infliximab: A Dynamic Survival Model
1434957	11	4.25	90	802		X		3	5	4	5	United States	Racial Differences in Fistulizing Perianal Crohn's Disease
1434963	11	4.25	91	803				4	6	4	3	France	Long-Term Efficacy of Adalimumab for Treatment of Moderately to Severely Active Ulcerative Colitis
1435140	11	4.25	92	804				3	7	4	3	United States	The Cecal Patch is Associated with a Greater Prevalence of Symptoms in Patients with Ulcerative Colitis
1403321	11	4.5	98	977				3	5	3	7	United States	A Pilot Study to Improve Maintenance Medication Adherence in Adult Inflammatory Bowel Disease Patients
1404400	11	4.5	99	978				4	4	4	6	United States	Compliance of Inflammatory Bowel Disease Patients with Guideline Recommendations for Laboratory Monitoring: Colonoscopic Surveillance and DEXA Scanning
1408484	11	4.5	100	979				6	3	4	5	United States	Antibodies to Clostridium Difficile Toxins in Inflammatory Bowel Disease Patients

1=Excellent - 9=Poor (C=Conflict of Interest)

ACG 2012 All Scores Report by Category and Score - Blinded

Control ID	Cat	Avg	Rank Cat	Rank All	Poster Only	ACG Grant	Revisions				Country	TITLE
							Rev1	Rev2	Rev3	Rev4		
1418921	11	4.5	101	980			4 Rev1	7 Rev2	4 Rev3	3 Rev4	United States	New-Onset Inflammatory Bowel Disease During Tumor Necrosis Factor-Alpha Inhibitor Therapy for Rheumatoid Arthritis and Juvenile Rheumatoid Arthritis: A Review of the Food and Drug Administration Adverse Event Reporting System and Literature.
1426104	11	4.5	102	981	X		6 Rev1	4 Rev2	3 Rev3	5 Rev4	United Kingdom	Vitamin D deficiency is widely prevalent in South Asian patients with inflammatory bowel disease
1426759	11	4.5	103	982	X		5 Rev1	5 Rev2	3 Rev3	5 Rev4	United States	Comparing Disease Characteristics between African-American and Caucasian Inflammatory Bowel Disease Patients
1427737	11	4.5	104	983			6 Rev1	4 Rev2	3 Rev3	5 Rev4	United States	Efficacy of Oral Mesalazine Monotherapy (5-ASA) versus Combination Oral Mesalazine Plus Proton Pump Inhibitor (5-ASA/PPI) Therapy in the Treatment of Ulcerative Colitis (UC).
1427789	11	4.5	105	984			5 Rev1	6 Rev2	3 Rev3	4 Rev4	United States	Demographic Difference of Hepatosplenic T-Cell Lymphoma (HSTCL) versus Non-HSTCL Lymphoma in Patients with IBD Receiving Thiopurines: A Population Cohort Analysis
1429451	11	4.5	106	985			5 Rev1	4 Rev2	5 Rev3	4 Rev4	United States	The Burden of Inflammatory Bowel Disease: A Patient-Reported Qualitative Analysis
1432146	11	4.5	107	986			8 Rev1	4 Rev2	4 Rev3	2 Rev4	United States	The use of Human Anti-Chimeric Antibody (HACA) and Infliximab Levels in the Management of Inflammatory Bowel Disease
1433751	11	4.5	108	987			5 Rev1	7 Rev2	3 Rev3	3 Rev4	Denmark	Neutralization of interleukin 21 using a monoclonal antibody results in suppression of experimental colitis.
1433839	11	4.5	109	988			4 Rev1	7 Rev2	4 Rev3	3 Rev4	United States	Corticosteroid Avoidance in Patients With Crohn's Disease Who Are Newly Initiated to Therapy With an Anti-TNF Versus Azathioprine
1434065	11	4.5	110	989			5 Rev1	6 Rev2	4 Rev3	3 Rev4	United States	Vitamin D status in patients with microscopic colitis
1427348	11	4.75	123	1151			6 Rev1	6 Rev2	2 Rev3	5 Rev4	Egypt	Antigliyan Antibodies in Diagnosis, Phenotyping and Behavior in Egyptian Patients with Crohn's Disease
1427753	11	4.75	124	1152			6 Rev1	6 Rev2	5 Rev3	2 Rev4	United States	Is IBD a Risk Factor for Myelodysplastic Syndrome (MDS)?
1429019	11	4.75	125	1153			6 Rev1	7 Rev2	4 Rev3	2 Rev4	United States	Tumor Necrosis Factor-alpha blockers do not augment the risk of viral infection in inflammatory bowel disease (IBD): A review of the Food and Drug Administration Adverse Event Reporting System (FDA AERS).
1432827	11	4.75	126	1154			6 Rev1	5 Rev2	4 Rev3	4 Rev4	France	Comparative Colorectal Cancer Risk in Patients With Ulcerative Colitis Treated With Adalimumab Versus Conventional Therapy
1432891	11	4.75	127	1155			6 Rev1	5 Rev2	4 Rev3	4 Rev4	France	Risk of Malignancy, Infection, Serious Infection, and Acute Health Care Use in Patients With Crohn's Disease Treated With Adalimumab vs. Immunosuppressants
1427377	11	5	136	1323			6 Rev1	6 Rev2	4 Rev3	4 Rev4	United States	Significant correlation between interferon- (IFN-) γ secretion by T cells in peripheral blood with disease severity in Crohn's disease but not in Ulcerative colitis.
1428686	11	5	137	1324			6 Rev1	4 Rev2	CI Rev3	CI Rev4	United States	Impact on Quality of Life of a Smart Device Mobile Application in Patients with Inflammatory Bowel Disease

1=Excellent - 9=Poor (CI=Conflict of Interest)

ACG 2012 All Scores Report by Category and Score - Blinded

Control ID	Cat	Avg	Rank Cat	Rank All	Poster Only	ACG Grant	Rev1	Rev2	Rev3	Rev4	Country	TITLE
1430092	I1	5	138	1325			7 Rev1	4 Rev2	4 Rev3	5 Rev4	United States	Environmental Changes and the onset of Inflammatory Bowel Disease (IBD) in the Migrant South Asian Population
1432810	I1	5	139	1326			6 Rev1	5 Rev2	4 Rev3	5 Rev4	United States	Immunization Status in Patients with Inflammatory Bowel Diseases and Rheumatologic Disorders Receiving Infliximab Infusions: Results of a Patient Survey in a Tertiary Care Center.
1403987	I1	5.25	145	1458	X		7 Rev1	6 Rev2	3 Rev3	5 Rev4	United States	The Search for Phenotypic Differences in IBD Between AfroCaribbeans and AfroAmericans.
1404402	I1	5.25	146	1459	X		8 Rev1	6 Rev2	3 Rev3	4 Rev4	United States	Primary Sclerosing Cholangitis and its Relationship to the Colon in a Cohort of Inflammatory Bowel Disease Patients of African Descent
1414410	I1	5.25	147	1460	X		6 Rev1	5 Rev2	5 Rev3	5 Rev4	United States	Hypogonadism in Male Patients with Inflammatory Bowel Disease
1422339	I1	5.25	148	1461	X		6 Rev1	6 Rev2	5 Rev3	4 Rev4	United Kingdom	CT Enterography remains a valuable tool for the assessment of Crohn's disease
1426156	I1	5.25	149	1462	X		7 Rev1	6 Rev2	3 Rev3	5 Rev4	United Kingdom	Phenotypic characterisation of Inflammatory Bowel Disease in South Asians in the United Kingdom-Insights into a shifting landscape.
1426397	I1	5.25	150	1463			7 Rev1	8 Rev2	3 Rev3	3 Rev4	United States	SP-333, a proteolysis-resistant agonist of guanylate cyclase-C, inhibits activation of NF-κB and suppresses production of inflammatory cytokines to ameliorate DSS-induced colitis in mice
1426585	I1	5.25	151	1464	X		5 Rev1	7 Rev2	4 Rev3	5 Rev4	United States	False Positive Infliximab Levels Detected in Patients Treated With Adalimumab For Inflammatory Bowel Disease
1413881	I1	5.5	158	1588			7 Rev1	6 Rev2	4 Rev3	5 Rev4	United States	Colonoscopic Evidence of Active Ulcerative Colitis Leads to Medication Changes in the Majority of Patients.
1427798	I1	5.5	159	1589	X		7 Rev1	6 Rev2	5 Rev3	4 Rev4	United Kingdom	CT Enterography is a useful test in the investigation of small bowel disease
1427918	I1	5.5	160	1590			7 Rev1	6 Rev2	4 Rev3	5 Rev4	United States	Clinical Implications of Measuring Infliximab Levels and Human Anti-Chimeric Antibodies in Patients with Inflammatory Bowel Disease
1432301	I1	5.5	161	1591			5 Rev1	5 Rev2	5 Rev3	7 Rev4	France	Benefit-Risk Assessment of Adalimumab as Maintenance Treatment for Ulcerative Colitis: NEAR Analysis of Week 8 Responders in UL TRA 2
1432407	I1	5.5	162	1592	X		6 Rev1	7 Rev2	7 Rev3	2 Rev4	United States	Gastric Signet Ring Cell Adenocarcinoma in a Patient Recently Started on Infliximab with a Normal Esophagogastroduodenoscopy 10 Months Earlier
1432619	I1	5.5	163	1593			7 Rev1	7 Rev2	5 Rev3	3 Rev4	United States	Concomitant Antibiotic Usage Does Not Further Increase the Risk of Inflammatory Bowel Disease with Isotretinoin Treatment for Acne: A Review of the Food and Drug Administration Adverse Event Reporting System
1433416	I1	6.5	164	1594			4 Rev1	8 Rev2	5 Rev3	5 Rev4	United States	Pneumocystis Jiroveci Pneumonia in Inflammatory Bowel Disease Patients: A Survey of Prophylaxis Patterns among Gastroenterology Providers

1=Excellent - 9=poor (C=Conflict of Interest)

ACG 2012 All Scores Report by Category and Score - Blinded

Control ID	Cat	Avg	Rank Cat	Rank All	Poster Only	ACG Grant	Rev1	Rev2	Rev3	Rev4	Country	TITLE
1434294	I1	5.5	165	1595			7 Rev1	8 Rev2	4 Rev3	3 Rev4	United States	Tumor necrosis factor-alpha (TNF-α) blocker monotherapy and in combination with immunomodulators and corticosteroids, augment the risk of mycobacterial infections: A review of the Food and Drug Administration Adverse Event Reporting System (FDA AERS).
1407505	I1	5.75	167	1697			7 Rev1	8 Rev2	3 Rev3	5 Rev4	United States	Orally administered SP-333, a guanylate cyclase-C agonist, acts locally in the lumen of the distal intestine to ameliorate DSS-induced colitis in mice
1427787	I1	5.75	168	1698			7 Rev1	6 Rev2	5 Rev3	5 Rev4	United States	Is Medication Dose a Risk Factor for Lymphoma in IBD Patients taking Azathioprine/6-Mercaptopurine?
1433291	I1	5.75	169	1699			7 Rev1	5 Rev2	6 Rev3	5 Rev4	United States	Inflammatory Bowel Disease in the Central Valley of California: A Community Safety Net Medical Center Experience
1411968	I1	6	177	1786	X		6 Rev1	6 Rev2	6 Rev3	6 Rev4	United States	Fulminant Colitis following Rituximab therapy for Disseminated B Cell Marginal Lymphoma
1435121	I1	6	178	1787			6 Rev1	7 Rev2	5 Rev3	6 Rev4	United States	A Health Survey of Gastroenterologist Prescribing Practices with Adalimumab for Crohn's Disease
1403992	I1	6.25	179	1847	X		8 Rev1	6 Rev2	5 Rev3	6 Rev4	United States	The Heart of the Matter: An Echocardiographic Evaluation of Inflammatory Bowel Disease
1430877	I1	6.25	180	1848	X		7 Rev1	6 Rev2	6 Rev3	6 Rev4	Portugal	Disseminated tuberculosis in a patient with Crohn's disease on adalimumab
1434485	I1	6.25	181	1849			7 Rev1	9 Rev2	4 Rev3	5 Rev4	United States	Differentiating the risk of bacterial infections between individual tumor necrosis factor-alpha (TNF-α) blockers in inflammatory bowel disease: A review of the Food and Drug Administration Adverse Event Reporting System (FDA AERS)
1434503	I1	6.25	182	1850			7 Rev1	6 Rev2	6 Rev3	6 Rev4	Canada	Guillain-Barré Syndrome in Ulcerative Colitis Following Treatment with Infliximab
1427894	I1	7	190	1952			7 Rev1	7 Rev2	7 Rev3	7 Rev4	United States	Concurrent Erythema Nodosum and Pyoderma Gangrenosum in a Patient with Inflammatory Bowel Disease Unclassified
1430912	I1	7	191	1953	X		7 Rev1	6 Rev2	8 Rev3	7 Rev4	United States	Primary small bowel Adenocarcinoma in the setting of Chronic Crohn's disease
1434616	I1	7.75	194	1992			7 Rev1	9 Rev2	9 Rev3	6 Rev4	United States	Tumor necrosis factor-alpha blocker monotherapy or in combination with immunomodulators or systemic corticosteroids does not augment the risk of bacterial infections: A review of the Food and Drug Administration Adverse Event Reporting System (FDA AERS).

ACG 2012 All Scores Report by Category and Score - Blinded

I. IBD 2012 Scale 1 Best to 10 Worst

Control ID	Cat	Avg	Rank	Rank All	Poster Only	ACG Grant	Rev1	Rev2	Rev3	Rev4	Country	TITLE
1438550	12	2	3	25			1 Rev1	5 Rev2	1 Rev3	1 Rev4	United States	A Phase 3 Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Subcutaneous Golimumab Maintenance Therapy in Patients with Moderately to Severely Active Ulcerative Colitis: PURSUIT-Maintenance
1440781	12	2	4	26			1 Rev1	3 Rev2	1 Rev3	3 Rev4	United States	Lymphoproliferative Disorders in Patients Receiving Thiopurines for Ulcerative Colitis: A Nationwide 10-Year Retrospective Cohort from the Veterans Affairs Healthcare System
1439130	12	2.25	6	40	X		2 Rev1	2 Rev2	1 Rev3	4 Rev4	United States	Influence of Trough Serum Drug Level and Immunogenicity on the Lack of Response to Adalimumab Therapy in IBD Patients
1440415	12	2.25	7	41			2 Rev1	2 Rev2	2 Rev3	3 Rev4	United States	The Natural History of Systemic Corticosteroid Therapy in Ulcerative Colitis: A Nationwide, Retrospective Cohort from the Veterans Affairs Healthcare System
1437678	12	2.5	9	60	X		2 Rev1	2 Rev2	3 Rev3	3 Rev4	United States	Effects of Operation Iraqi Freedom and Operation Enduring Freedom on Inflammatory Bowel Disease
1438953	12	2.67	10	65			2 Rev1	CI Rev2	4 Rev3	2 Rev4	United States	Assessment of Therapy Changes and Drug Discontinuation among Operative Colitis Patients using Health Claims Data
1436995	12	2.75	14	98			3 Rev1	4 Rev2	2 Rev3	2 Rev4	Canada	Postoperative complications in Crohn's disease and ulcerative colitis patients - A province-wide cohort study
1437047	12	2.75	15	99			2 Rev1	3 Rev2	2 Rev3	4 Rev4	United States	Does abdomino-pelvic CT done during emergency department visit affect management in patients with inflammatory bowel diseases?
1438621	12	2.75	16	100			2 Rev1	5 Rev2	1 Rev3	3 Rev4	United States	Certolizumab Pegol Plasma Concentrations and Endoscopic and Clinical Outcomes in Crohn's Disease: A Post Hoc Analysis of the MUSIC Trial
1440488	12	2.75	17	101			2 Rev1	3 Rev2	3 Rev3	3 Rev4	United States	Natural History of Ulcerative Colitis by the Age Group at Diagnosis: A 10-Year Nationwide Retrospective Cohort from the Veterans Affairs Healthcare System
1438791	12	3	21	168			4 Rev1	CI Rev2	2 Rev3	3 Rev4	United States	The Effect of Ulcerative Colitis (UC) Remission Status After Induction With MMX[®] Mesalazine on Long-Term Maintenance Therapy Outcomes (MOMENTUM Study): Induction Phase Results
1440187	12	3	22	169			4 Rev1	2 Rev2	1 Rev3	5 Rev4	United States	Association of vitamin D and genetic variation in IBD
1435985	12	3.25	28	256			5 Rev1	4 Rev2	2 Rev3	2 Rev4	United States	Cumulative Risk of Non-Melanoma Skin Cancer in a Population-Based Cohort of Inflammatory Bowel Disease
1437184	12	3.25	29	257			1 Rev1	4 Rev2	5 Rev3	3 Rev4	United States	Increased Risk of Non-Alcoholic Fatty Liver Disease Among Patients with Inflammatory Bowel Disease
1439233	12	3.33	30	267			2 Rev1	CI Rev2	4 Rev3	4 Rev4	United States	Assessment of Therapy Changes and Drug Discontinuation among Crohn's Disease Patients using Health Claims Data
1437232	12	3.5	39	368			4 Rev1	3 Rev2	3 Rev3	4 Rev4	United States	Immunization Rates and Vaccine Beliefs in Patients with Inflammatory Bowel Diseases: An Opportunity for Improvement
1439168	12	3.5	40	369			3 Rev1	5 Rev2	3 Rev3	3 Rev4	United States	Efficacy of and Factors Contributing to Dose Adjustment in Treatment with Certolizumab for Crohn's Disease
1439833	12	3.5	41	370			2 Rev1	3 Rev2	4 Rev3	5 Rev4	United States	Obesity is linked to higher rates of arthritis and failure to biologics in IBD patients.

1=Excellent - 9=Poor (CI=Conflict of Interest)

ACG 2012 All Scores Report by Category and Score - Blinded

Control ID	Cat	Avg	Rank Cat	Rank All	Poster Only	ACG Grant	TITLE				Country	TITLE
							Rev1	Rev2	Rev3	Rev4		
1440193	12	3.5	42	371			3	6	2	3	Canada	The Risks of Post-operative Complications Following Pre-operative Infliximab Therapy for Crohn's Disease in Patients Undergoing Abdominal Surgery: a Systematic Review and Meta-analysis
1440513	12	3.5	43	372			5	2	4	3	United States	Methotrexate in ulcerative colitis: a nationwide retrospective cohort from the Veterans Affairs healthcare system.
1440561	12	3.5	44	373			3	3	4	4	United States	Steroid Saving Efficacy of Azathioprine: a Nationwide Retrospective Cohort from the Veterans Affairs Healthcare System
1437808	12	3.67	46	388			5	CI	2	4	United States	Natalizumab in Crohn's Disease: Results from a US tertiary IBD center
1440872	12	3.67	47	389			4	CI	3	4	United States	Correlation Between Clinical, Endoscopic, and Histologic Disease Activity in Ulcerative Colitis
1435501	12	3.75	54	494			3	5	4	3	United States	Unplanned Hospital Readmissions in IBD Patients: Predictive Factors
1436111	12	3.75	55	495			2	6	3	4	United States	Chromoendoscopy in Community GI: A Single Physician Experience
1436885	12	3.75	56	496			2	7	3	3	United States	Infection Rates with Infliximab in Inflammatory Bowel Disease Compared to Rheumatologic Diseases: A Single Center Experience
1437059	12	3.75	57	497			2	8	2	3	Australia	Fecal Microbiota Transplantation in Ulcerative Colitis: Review of 24 years Experience
1437733	12	3.75	58	498			5	2	3	5	United States	RESPONSE TO VITAMIN D SUPPLEMENTATION IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH VITAMIN D DEFICIENCY: A TERTIARY CARE CENTER EXPERIENCE.
1438518	12	3.75	59	499			3	6	2	4	United States	The Presence of Primary Sclerosing Cholangitis Is Associated with A Lower Risk For Crohn's Disease of the ileal Pouch
1439072	12	3.75	60	500			4	5	4	2	United States	Mean Corpuscular Volume (MCV) to White Blood Cell (WBC) Count Ratio as a Clinical Predictor of Response to Thiopurine Medications in Patients with Inflammatory Bowel Disease
1439890	12	3.75	61	501			5	3	3	4	United States	Risk Factors for Depression in the Elderly Inflammatory Bowel Disease Population
1439980	12	3.75	62	502			5	2	4	4	United States	Prevalence of Vitamin D deficiency and insufficiency in Inflammatory Bowel Disease (IBD) patients from the Sunshine State.
1440113	12	3.75	63	503			2	4	4	5	United States	Impact of Obesity on Inflammatory Bowel Disease (IBD)
1440313	12	3.75	64	504			2	5	3	5	United States	Quantiferon testing is superior to tuberculosis skin test (TST) in identifying latent TB in immunosuppressed patients with inflammatory bowel disease: A decision analysis
1441113	12	3.75	65	505	X		5	3	5	2	United States	Health Care Expenditure for Ulcerative Colitis Adult Patients for the Years 2007 to 2009: A Nationwide Estimate using Medical Expenditure Panel Survey
1435473	12	4	75	659			5	3	5	3	United States	Unplanned Hospital Readmission Rates and Causes in Patients with Inflammatory Bowel Disease: A Critical Analysis

1=Excellent - 9=Poor (CI=Conflict of Interest)

ACG 2012 All Scores Report by Category and Score - Blinded

Control ID	Cat	Avg	Rank Cat	Rank All	Poster Only	ACG Grant	Revisions				Country	TITLE
							Rev1	Rev2	Rev3	Rev4		
1436293	12	4	76	660	X		3 Rev1	4 Rev2	4 Rev3	5 Rev4	Austria	DETECTION OF ANTI INFLIXIMAB ANTIBODIES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD) IN THE PRESENCE OF INFLIXIMAB BY HOMOGENEOUS LIQUID PHASE ANTI INFLIXIMAB MOBILITY SHIFT ASSAY
1436428	12	4	77	661			5 Rev1	3 Rev2	6 Rev3	2 Rev4	United States	Oral administration of AVX-470n, a novel anti-TNF antibody, suppresses inflammation in a murine model of inflammatory bowel disease
1436534	12	4	78	662			3 Rev1	4 Rev2	4 Rev3	5 Rev4	United States	CLINICAL EXPERIENCE WITH MEASUREMENT OF SERUM INFLIXIMAB AND ANTIBODIES TO INFLIXIMAB USING A NEW HOMOGENEOUS MOBILITY SHIFT ASSAY: RESULTS OF A MULTI-CENTER OBSERVATIONAL STUDY
1436634	12	4	79	663			2 Rev1	5 Rev2	5 Rev3	CI Rev4	United States	Low Rate of Clostridium difficile Infection Testing in Patients with Newly Diagnosed Inflammatory Bowel Disease and Diarrhea
1436813	12	4	80	664			5 Rev1	2 Rev2	5 Rev3	4 Rev4	United States	Patient Perception of Chronic Illness Care is associated with Quality of Life in Inflammatory Bowel Diseases
1437415	12	4	81	665			3 Rev1	3 Rev2	4 Rev3	6 Rev4	United States	Immunoglobulin G And Subclass Deficiency is Common In Patients With Inflammatory Bowel Disease
1438692	12	4	82	666			3 Rev1	4 Rev2	5 Rev3	4 Rev4	United States	Autoimmune Hepatitis Is Associated with a High Prevalence of Gut Inflammatory Disorders
1436422	12	4.25	93	805			3 Rev1	6 Rev2	4 Rev3	4 Rev4	United States	Long-term follow-up study of fecal microbiota transplantation (FMT) for ulcerative colitis (UC)
1440697	12	4.25	94	806			5 Rev1	4 Rev2	4 Rev3	4 Rev4	United States	The Rates of Testing For Bone Mineral Density in Ulcerative Colitis: A Nationwide Database Analysis.
1436119	12	4.33	95	832			4 Rev1	CI Rev2	4 Rev3	5 Rev4	United States	Assessment of the Relationship between Quality of Sleep and Disease Activity in Inflammatory Bowel Disease (IBD) Patients
1436947	12	4.33	96	833			4 Rev1	CI Rev2	3 Rev3	6 Rev4	United States	Systematic review of thiopurines and the risk of colorectal neoplasia in ulcerative colitis
1440348	12	4.33	97	834			3 Rev1	5 Rev2	5 Rev3	CI Rev4	United States	Remestemcel-L therapy is effective treatment in patients with refractory Crohn's disease. Simon Lichtiger MD, Linda Custer Phd.
1437049	12	4.5	111	990			2 Rev1	5 Rev2	6 Rev3	5 Rev4	United States	LOW BONE MINERAL DENSITY IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH VITAMIN D DEFICIENCY IN A TERTIARY CARE CENTER
1437063	12	4.5	112	991	X		4 Rev1	3 Rev2	6 Rev3	5 Rev4	Canada	The Effect of Liver Transplantation for Primary Sclerosing Cholangitis on Disease Activity in Patients with Inflammatory Bowel Disease
1437682	12	4.5	113	992			5 Rev1	3 Rev2	5 Rev3	5 Rev4	United States	PATTERNS OF VITAMIN D DEFICIENCY IN INFLAMMATORY BOWEL DISEASE: TERTIARY CARE REFERRAL STUDY
1437780	12	4.5	114	993			5 Rev1	5 Rev2	3 Rev3	5 Rev4	United States	Meta-Analysis of the Efficacy and Safety of Bisphosphonate Therapy in Inflammatory Bowel Disease
1438572	12	4.5	115	994			5 Rev1	4 Rev2	4 Rev3	5 Rev4	United States	Clinical Significance of Surveillance Pouchoscopy in Asymptomatic Heal Pouch Patients with Underlying Inflammatory Bowel
1438812	12	4.5	116	995			5 Rev1	4 Rev2	5 Rev3	4 Rev4	United States	Diagnosis of Crohn's disease after age 60 is associated with lower prevalence of penetrating phenotype

1=Excellent - 9=Poor (CI=Conflict of Interest)

ACG 2012 All Scores Report by Category and Score - Blinded

Control ID	Cat	Avg	Rank Cat	Rank All	Poster Only	ACG Grant	TITLE				Country	
							Rev1	Rev2	Rev3	Rev4		
1439046	12	4.5	117	996	X		4 Rev1	7 Rev2	3 Rev3	4 Rev4	Japan	Mucosal Healing Can Promote Favorable Outcome in Patients with Crohn's Disease after Endoscopic Dilatation of the Small Intestinal Stenosis.
1439380	12	4.5	118	997			6 Rev1	6 Rev2	4 Rev3	2 Rev4	United States	Biologics do not reduce the long term risk of surgery in patients with IBD
1439394	12	4.5	119	998			5 Rev1	4 Rev2	5 Rev3	4 Rev4	United States	Type 3 Muscarinic Receptors Modulate Macrophage Phenotype in the Presence of Th2 Cytokines
1439720	12	4.5	120	999			4 Rev1	6 Rev2	4 Rev3	4 Rev4	United States	The use of oral complementary and alternative medicine in patients with Inflammatory bowel disease.
1440357	12	4.5	121	1000			4 Rev1	6 Rev2	2 Rev3	6 Rev4	United States	Backwash Ileitis And The Risk Of Neoplasia In Ulcerative Colitis Patients Undergoing Restorative Proctocolectomy
1440677	12	4.5	122	1001			4 Rev1	5 Rev2	4 Rev3	5 Rev4	United States	Bone Disease in Male Veterans with Ulcerative Colitis: 10-Year Nationwide Study.
1436790	12	4.75	128	1156	X		5 Rev1	4 Rev2	5 Rev3	5 Rev4	United States	Do Hispanics receive the same medical treatment for inflammatory bowel disease as non-Hispanics?
1437154	12	4.75	129	1157	X		4 Rev1	6 Rev2	5 Rev3	4 Rev4	United Kingdom	Incidental diagnosis of Inflammatory Bowel Disease in a British Bowel Cancer Screening cohort: a further experience of incidental incidence.
1437209	12	4.75	130	1158	X		3 Rev1	6 Rev2	6 Rev3	4 Rev4	United Kingdom	Incidental diagnosis of Inflammatory Bowel Disease from the British Bowel Cancer Screening programme: follow-up data from the first reported cohort.
1437261	12	4.75	131	1159	X		5 Rev1	3 Rev2	5 Rev3	6 Rev4	United Kingdom	The accuracy of pre bone mineral density FRAX scores in predicting need for treatment in patients with Inflammatory Bowel Disease at risk of Osteoporosis.
1438871	12	4.75	132	1160			4 Rev1	5 Rev2	4 Rev3	6 Rev4	Puerto Rico	Comorbidities in Hispanics with IBD: The Protective Effect of IBD in the Development of Arterial Hypertension
1439303	12	4.75	133	1161			3 Rev1	7 Rev2	5 Rev3	4 Rev4	United States	Infliximab in treatment of IBD- Longevity based upon type of disease
1439727	12	4.75	134	1162			4 Rev1	7 Rev2	5 Rev3	3 Rev4	United States	Involvement of Upper Gastrointestinal Tract in Patient with Ulcerative Colitis
1440933	12	4.75	135	1163	X		5 Rev1	6 Rev2	3 Rev3	5 Rev4	United States	Long-Term Outcomes of Thalidomide in Refractory Inflammatory Bowel Disease
1435896	12	5	140	1327			4 Rev1	4 Rev2	6 Rev3	6 Rev4	Germany	Digital holographic microscopy for assessment of experimental colitis and monitoring of intestinal wound healing in vitro
1436548	12	5	141	1328			5 Rev1	5 Rev2	6 Rev3	4 Rev4	Denmark	NKG2D expression and function of T cells differs in inflammatory bowel disease
1436942	12	5	142	1329			5 Rev1	7 Rev2	5 Rev3	3 Rev4	United States	Incidence and Predictors of Active Cytomegalovirus Infection in Inflammatory Bowel Disease Patients with Severe Colitis: an Outcomes-Based Analysis in a Large Academic Institution
1439671	12	5	143	1330			7 Rev1	4 Rev2	6 Rev3	3 Rev4	United States	Use of biologics is not associated with lower prevalence of Extra Intestinal Manifestations (EIMs) in IBD.
1440696	12	5	144	1331			5 Rev1	5 Rev2	6 Rev3	4 Rev4	United States	Health Care Disparity and IBD Outcomes: Does Insurance Status Affect Measures of Disease Activity in Crohn Disease?

ACG 2012 All Scores Report by Category and Score - Blinded

Control ID	Cat	Avg	Rank Cat	Rank All	Poster Only	ACG Grant	TITLE				Country	
							Rev1	Rev2	Rev3	Rev4		
1437262	12	5.25	152	1465			3	8	4	6	United States	Immune Response and Safety of Herpes Zoster Vaccine in IBD Patients on Mesalazine or Thiopurines
1437602	12	5.25	153	1466			5	6	5	5	United States	Differential Gene Expression and Pathway Analysis Of Colonic Biopsies and Peripheral Blood Mononuclear Cells In Ulcerative Colitis Patients Highlighting Disease-Specific Genetic and Immunological Markers
1437803	12	5.25	154	1467			4	6	4	7	Saudi Arabia	Clinical epidemiology and phenotypic characteristics of Ulcerative Colitis in Saudi Arabia
1438886	12	5.25	155	1468			5	4	5	7	United States	Effect of MMX[®] Mesalamine Coadministration on the Pharmacokinetics of Ciprofloxacin XR
1439301	12	5.25	156	1469			6	7	5	3	United States	Does 5ASA therapy prevent the development of premalignant polyps in chronic idiopathic ulcerative colitis?
1440972	12	5.25	157	1470			5	6	5	5	United States	Steroids and Thiopurines Use in Ulcerative Colitis Patients: Analysis of a 10-Year Nationwide Database from the Veterans Affairs Healthcare System
1438961	12	5.5	166	1596			5	4	6	7	United States	Effects of MMX[®] Mesalamine Coadministration on the Pharmacokinetics of Mesalazine
1436750	12	5.75	170	1700			6	6	5	6	United States	Use of psychotropics, depression and anxiety in patients with inflammatory bowel diseases are not associated with anemia, iron deficiency or inflammatory markers
1437012	12	5.75	172	1702			5	6	5	7	United Kingdom	M/R Enterography is a useful test in the investigation of small bowel disease
1437536	12	5.75	173	1703	X		7	7	4	6	Canada	Oral corticosteroids for induction of remission in ulcerative colitis
1438696	12	5.75	174	1704			6	6	5	5	Australia	Resistant Fistulizing Crohns Disease treated with combination of Infliximab, Anti-MAP and Hyperbaric Oxygen (HBO).
1438821	12	5.75	175	1705	X		8	6	6	3	United States	Health maintenance in patients with Inflammatory Bowel Disease in the City Hospital
1439622	12	5.75	176	1706	X		5	6	6	6	Puerto Rico	Unusual coexistence of ulcerative colitis, primary sclerosing cholangitis and Menetrier's disease.
1436762	12	6.25	183	1851	X		6	5	9	3	United Kingdom	Dose Intensification with anti-TNF agents in Inflammatory Bowel Disease- a secondary care experience.
1440175	12	6.25	184	1852			6	8	6	6	United Kingdom	Magnetic Resonance Enterography for the assessment of Crohn's disease: Changing imaging paradigms?
1440300	12	6.25	185	1853			7	5	6	5	Canada	Detecting microparticles in human intestine in patients with Inflammatory Bowel Disease with synchrotron based X-ray beamline
1436550	12	6.5	186	1889	X		8	7	7	7	United States	Abnormal Bone Density in IBD Patients
1438925	12	6.5	187	1890	X		5	7	6	8	United States	Antibiotic-induced DRESS Syndrome: A Rare Complication in a Patient with Crohn's Disease
							5	7	6	8	United States	Appendiceal inversion in a patient with Crohn's disease: A Case Report

1=Excellent - 9=Poor (C=Conflict of Interest)

ACG 2012 All Scores Report by Category and Score - Blinded

Control ID	Cat	Avg	Rank Cat	Rank All	Poster Only	ACG Grant	TITLE				Country	TITLE
							Rev1	Rev2	Rev3	Rev4		
1440834	12	6.5	188	1891	X		8	8	6	4	United States	Factors Influencing The Treatment of Inflammatory Bowel Disease in Patients With Cancer Recurrence: Pilot Study.
1437662	12	6.75	189	1924	X		6	7	9	5	United States	Distribution of Inflammatory Bowel Disease (IBD) among African Americans (AA) and Hispanics (HS) at an Inner City Hospital
1437505	12	7.25	192	1977			6	8	9	6	United States	Racial disparities in CRP and ESR levels in Inflammatory Bowel Disease
1440707	12	7.25	193	1978	X		7	7	9	6	Canada	Use of Immunomodulators and anti-TNF agents in patients admitted with an exacerbation of crohn's disease in St. Johns.
1437265	12	7.75	195	1993			7	8	8	8	United States	Benign Course of Crohn's Disease with Late-Elderly Onset